BioIntelliSense BioButton™ Named CES 2021 Best of Innovation Award Honoree

BioButton medical-grade wearable device and data services built in response to COVID-19 pandemic

Denver, CO – December 15, 2020 – BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced that it has been named Best of Innovation as a CES® 2021 Innovation Awards Honoree for the BioButton™ medical-grade wearable device and data services. The “Best of Innovation” award is given to only the highest-rated product in each category and is not assured for any category in any year unless the total scores for a product exceed an exceptional threshold. The innovation award announcement was made ahead of the first all-digital CES 2021, the world’s most influential technology event, happening January 11-14, 2021.

The BioButton is a coin-sized, disposable medical wearable device for continuous monitoring of temperature, heart rate and respiratory rate at rest to enable early detection of adverse vital sign trends through its proprietary biosensor technology and advanced analytics. Its effortless user experience design and multi-parameter capability makes remote monitoring scalable, reliable and cost effective.

“We are extremely honored to be named Best of Innovation as a CES 2021 Innovation Award honoree. The commercial launch of the BioButton COVID-19 symptom screening and vaccine monitoring solution is timely in addressing the growing challenge of safe return to worksites, school, travel, conferences and entertainment” said James Mault, MD, CEO of BioIntelliSense. “The BioButton is the newest addition to our biosensor portfolio and data services model for public health and clinical applications that span infectious disease, orthopedics, oncology, and cardiac care.”
About BioIntelliSense

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ and BioButton™ devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care at home.

For more information on how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services, please contact us at info@biointellisense.com or visit our website at BioIntelliSense.com.

MEDIA CONTACT:
BioIntelliSense, Inc.
Carolyn Walsh
Chief Commercial Officer
cwalsh@BioIntelliSense.com